Duopharma Biotech’s ESG focus areas are distributed across the three pillars of Environment, Social and Governance, comprising Climate Performance, Sustainable Supply Chain, Access to Medicine, Diversity & Inclusion and Governance.
Since 2016, when we started our ESG journey, we have taken steps to reduce our emissions and environmental impact and improve the sustainability of our manufacturing process and materials. We have maintained and improved our ability to provide consumers and patients with access to the medicines and therapies they need for better health. We have also strengthened our team diversity to promote more inclusive perspectives, as well as refined our management system and corporate culture.
In March 2022, Duopharma Biotech announced its aspiration to achieve Carbon Neutrality by 2030, Net Zero Carbon Emissions by 2050 and to replace 50% of Single Use plastics with Biodegradable plastics within its operations by 2026.